MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is an open label, multi-center, randomized phase I/II study of MLN0128 versus standard
sorafenib. Eligible subjects in the phase I trial will receive MLN0128 in escalating doses.
Eligible subjects in the phase II trial will be 1:1 randomized to either the MLN0128 arm or
the sorafenib arm.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Bert O'Neil, MD Kathy Miller
Collaborators:
Big Ten Cancer Research Consortium Hoosier Cancer Research Network Millennium Pharmaceuticals, Inc.